1 / 24

News from American Society of Clinical Oncology Meeting June 2011 (Lung and Skin)

Paul Donnellan Consultant Medical Oncologist Galway University Hospitals. News from American Society of Clinical Oncology Meeting June 2011 (Lung and Skin). 1. Common causes of cancer death in the United States, 2008. Rudin C M et al. Clin Cancer Res 2009;15:5622-5625.

temple
Download Presentation

News from American Society of Clinical Oncology Meeting June 2011 (Lung and Skin)

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Paul Donnellan Consultant Medical Oncologist Galway University Hospitals News from American Society of Clinical Oncology Meeting June 2011(Lung and Skin) 1

  2. Common causes of cancer death in the United States, 2008 Rudin C M et al. Clin Cancer Res 2009;15:5622-5625 ©2009 by American Association for Cancer Research

  3. Melanoma: Mortality 4

  4. Clinical Images of Pigmented Lesions Tsao, H. et al. N Engl J Med 2004;351:998-1012

  5. Metastatic Melanoma • Young age at onset • Dismal prognosis • 1yr survival 25%; • 2yr survival 10% (Korn et al JCO 2008) • Chemotherapy ineffective • Dacarbazine (DTIC) • response rates 10% • median survival < 8 months • Never shown to improve survival 7

  6. High Dose Interleukin-2 • 16% respond (6% completely and for median duration 10 yrs)

  7. Immune ERU…

  8. . Kirkwood J M et al. JCO 2008;26:3445-3455

  9. Kaplan–Meier Curves for Overall Survival and Progression-free Survival in the Intention-to-Treat Population Hodi FS et al. N Engl J Med 2010;363:711-723

  10. Intracellular Signaling Pathways in Melanoma Known to Be Important in the Response and Resistance to Targeted Therapy. Smalley KS, Sondak VK. N Engl J Med 2010;363:876-878.

  11. Targeting Treatment to a Specific Variant in the Melanoma Gene. McDermott U et al. N Engl J Med 2011;364:340-350.

  12. Best Tumor Response for Each Patient. Chapman PB et al. N Engl J Med 2011. DOI: 10.1056/NEJMoa1103782

  13. Chapman PB et al. N Engl J Med 2011. DOI: 10.1056/NEJMoa1103782

  14. A 72-year-old man presented for evaluation of progressive dyspnea and cough McMullan, D. M. et al. N Engl J Med 2006;354:397

  15. Smoking image

  16. Lung Cancer

  17. Tarceva • Tablet once a day • Few side effects • If have the target mutation, the response to treatment is 5 times higher than with chemotherapy! • 55% vs 11%

  18. Crizotinib • Tablet once a day • Targets EML4-ALK (5% on NSCLC) • Few side effects • Dramatic response in patients who have failed chemotherapy • 90% patients respond • Randomised Clinical Trial UCHG

More Related